Technical Analysis for OCUL - Ocular Therapeutix, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 3.83% | |
| Wide Bands | Range Expansion | 3.83% | |
| Gapped Down | Weakness | 3.83% | |
| 20 DMA Resistance | Bearish | 0.67% | |
| Spinning Top | Other | 0.67% | |
| Earnings Movers | Other | 0.67% | |
| Inside Day | Range Contraction | 0.67% | |
| Wide Bands | Range Expansion | 0.67% | |
| 20 DMA Resistance | Bearish | 2.93% | |
| Earnings Movers | Other | 2.93% |
| Alert | Time |
|---|---|
| Up 5% | about 1 hour ago |
| 60 Minute Opening Range Breakout | about 2 hours ago |
| Rose Above Previous Day's High | about 2 hours ago |
| Up 3% | about 3 hours ago |
| Rose Above 20 DMA | about 3 hours ago |
Get a Trading Sidekick!
- Earnings date: 05/06/2024
Ocular Therapeutix, Inc. Description
Ocular Therapeutix, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapies based on its proprietary hydrogel platform technology for treating eye diseases and conditions. The company offers ReSure Sealant, a topical liquid hydrogel that creates a sealant to prevent post-surgical leakage from clear corneal incisions made during cataract surgery Its lead product candidates comprise OTX-DP, which is in Phase III clinical trials for the treatment of post-surgical ocular inflammation and pain; and OTX-TP that is in Phase II clinical trials for the treatment of glaucoma and ocular hypertension. The company's earlier stage product candidates include OTX-DP, which is in Phase II clinical trials for the treatment of allergic conjunctivitis; OTX-MP that has completed Phase I clinical trials for the treatment of bacterial conjunctivitis; and Anti-VEGF hydrogel depot, which is in preclinical testing for the treatment of wet AMD. Ocular Therapeutix, Inc. sells its ReSure Sealant through a network of independent medical device distributors in the United States. The company was founded in 2006 and is headquartered in Bedford, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Eye Inflammation Hypertension Clinical Trial Sealant Glaucoma Platform Technology Eye Diseases Cataracts Incision Treatment Of Glaucoma Allergic Conjunctivitis Cataract Surgery Cornea Allergology Incisions Ocular Hypertension Post Surgical Ocular Inflammation
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.31 |
| 52 Week Low | 1.995 |
| Average Volume | 2,656,808 |
| 200-Day Moving Average | 4.95 |
| 50-Day Moving Average | 8.03 |
| 20-Day Moving Average | 5.91 |
| 10-Day Moving Average | 5.30 |
| Average True Range | 0.60 |
| RSI (14) | 42.53 |
| ADX | 28.81 |
| +DI | 22.33 |
| -DI | 31.39 |
| Chandelier Exit (Long, 3 ATRs) | 6.56 |
| Chandelier Exit (Short, 3 ATRs) | 5.85 |
| Upper Bollinger Bands | 8.41 |
| Lower Bollinger Band | 3.41 |
| Percent B (%b) | 0.47 |
| BandWidth | 84.52 |
| MACD Line | -0.63 |
| MACD Signal Line | -0.80 |
| MACD Histogram | 0.1732 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 6.58 | ||||
| Resistance 3 (R3) | 6.56 | 6.28 | 6.44 | ||
| Resistance 2 (R2) | 6.28 | 6.07 | 6.28 | 6.39 | |
| Resistance 1 (R1) | 6.01 | 5.94 | 6.15 | 6.03 | 6.35 |
| Pivot Point | 5.73 | 5.73 | 5.79 | 5.73 | 5.73 |
| Support 1 (S1) | 5.46 | 5.52 | 5.60 | 5.48 | 5.15 |
| Support 2 (S2) | 5.18 | 5.39 | 5.18 | 5.11 | |
| Support 3 (S3) | 4.91 | 5.18 | 5.06 | ||
| Support 4 (S4) | 4.93 |
